Seery Virginia
Beth Israel Deaconess Medical Center.
Clin J Oncol Nurs. 2017 Aug 1;21(4 Suppl):76-86. doi: 10.1188/17.CJON.S4.76-86.
BACKGROUND: Talimogene laherparepvec (T-VEC) is the first intralesional therapy for melanoma approved by the U.S. Food and Drug Administration. This oncolytic viral immunotherapy has improved outcomes for patients with locoregional recurrent melanoma and is showing promise in combination with systemic therapies. .
OBJECTIVES: This article aims to provide oncology nurses with expert guidance on best practices in incorporating intralesional therapy for patients diagnosed with melanoma in practice. .
METHODS: Members of the Melanoma Nursing Initiative explored issues related to administration of T-VEC in melanoma. The current literature and clinical experiences were reviewed. .
The author offers a care step pathway (CSP) and commentary detailing best practices in infection control, drug storage, pharmacy interface, patient flow, space/staff allocation, patient education, and adverse event management with T-VEC. The CSP will help nurses improve patient outcomes and streamline the workflow with this novel therapeutic approach.
talimogene laherparepvec（T-VEC）是美国食品药品监督管理局批准的首个用于黑色素瘤的瘤内治疗药物。这种溶瘤病毒免疫疗法改善了局部复发性黑色素瘤患者的治疗效果，并且在与全身治疗联合使用时显示出前景。
本文旨在为肿瘤护理人员提供专业指导，介绍在实践中为诊断为黑色素瘤的患者采用瘤内治疗的最佳实践方法。
黑色素瘤护理倡议组织的成员探讨了与黑色素瘤患者使用T-VEC治疗相关的问题。对当前的文献和临床经验进行了综述。
作者提供了一个护理步骤路径（CSP）以及评论，详细阐述了在感染控制、药物储存、药房对接、患者流程、空间/人员分配、患者教育以及T-VEC不良事件管理方面的最佳实践方法。该CSP将帮助护士改善患者治疗效果，并通过这种新型治疗方法简化工作流程。
